

Press release – For immediate release July 7, 2025 – 5:45 pm CEST

# Disclosure of total number of voting rights and number of shares in the capital as of June 30, 2025

Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations.

#### Sophia Antipolis, France

Total number of shares	19,493,281
Number of real voting rights* (excluding treasury shares**)	19,409,273
Theoretical number of voting rights* (including treasury shares**)	19,470,081

(\*) Class E preference shares are non-voting (\*\*) pursuant to article 223-11 of the AMF's General Regulations



**About Median Technologies:** Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S.

and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.

### **Contacts**

## **Median Technologies**

Emmanuelle Leygues VP, Corporate Marketing & Financial Communications +33 6 10 93 58 88 emmanuelle.leygues@mediantechnologies.com

Investors - ACTIFIN
Ghislaine Gasparetto
+33 6 21 10 49 24
ghislaine.gasparetto@seitosei-actifin.com

## **Press – Ulysse Communication**

Bruno Arabian +33 6 87 88 47 26 <u>barabian@ulysse-communication.com</u> Nicolas Entz +33 6 33 67 31 54 <u>nentz@ulysse-communication.com</u>